<DOC>
	<DOCNO>NCT01142323</DOCNO>
	<brief_summary>The purpose study determine whether fenofibrate safe effective treatment primary sclerosing cholangitis ( PSC ) .</brief_summary>
	<brief_title>Fenofibrate PSC</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male female patient 18 75 year old Confirmed diagnosis PSC include typical finding stricturing dilatation intra and/or extrahepatic biliary duct radiographic exam , ( endoscopic retrograde cholangiopancreatography ERCP , percutaneous cholangiogram PTC magnetic resonance cholangiopancreatography MRCP ) Serum alkaline phosphatase level elevate least 1.5 time upper limit normal . Hypersensitivity fenofibrate Prisoners institutionalized subject Pregnant nursing woman Anticipated need liver transplantation one year Recipients liver transplantation Recurrent variceal hemorrhage , uncontrolled encephalopathy refractory ascites Coexisting liver disease include autoimmune viral hepatitis Acute chronic renal failure , define glomerular filtration rate ( GFR ) &lt; 60 ml/min , GFR calculate use Modification Diet Renal Disease ( MDRF ) GFR calculator Known cholecystitis Current use statin Current use coumadin anticoagulant therapy Previous history , know high risk , venous thromboembolism ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>